Slide 1: Preliminary Q2 and H1 2021 results
Preliminary Q2 and H1 2021 results July 13, 2021 Sample to Insight
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: This presentation contains both historical and forward-looking competitors' products; market acceptance of QIAGEN's new products and the integration of statements. All statements other than statements of historical fact are, or may b
Slide 3: Agenda
Agenda Introduction John Gilardi VP Corp Communications and IR Business and financial update Thierry Bernard Chief Executive Officer Roland Sackers Chief Financial Officer Q&A session Sample to Insight Preliminary Q2 2021 results 3
Slide 4: Overview Preliminary Q2 2021: Exceeded sales and adjusted EPS outlook
Overview 1 Preliminary Q2 2021: Exceeded sales and adjusted EPS outlook Preliminary Q2 and H1 2021 results • $567.3 m net sales (+28% actual, +24% CER vs. ~20% CER outlook) • $0.66-0.67 adj. diluted EPS expected ($0.65-0.66 CER vs. ~$0.62-0.64 Net sales Adjusted EPS(1) estimate CER outlook) (In $ mi
Slide 5: Sales by product groups
Preliminary Q2 and H1 2021 results: Sales by product groups (In $ million at actual rates / change in actual, CER rates) Q2 2021 Q2 2020 Actual CER H1 2021 H1 2020 Actual CER Sample technologies 203 200 1% -3% 430 354 21% 16% Diagnostic solutions(1) 154 87 76% 71% 304 183 66% 61% Of which QuantiFERO
Slide 6: Sales by non-COVID and COVID-19 product groups
Preliminary Q2 and H1 2021 results: Sales by non-COVID and COVID-19 product groups (In $ million at actual rates / change Q2 2021 Q2 2020 Actual CER % of sales H1 2021 H1 2020 Actual CER % of sales and % of 2021 sales in actual, CER rates) Non-COVID product groups 408 259 57% 52% 72% 772 562 37% 33%
Slide 7: Sales by geographic regions
Preliminary Q2 and H1 2021 results: Sales by geographic regions (In $ million at actual rates / change Q2 2021 Q2 2020 Actual CER % of sales H1 2021 H1 2020 Actual CER % of sales and % of 2021 sales in actual, CER rates) Americas 257 177 45% 44% 45% 501 351 43% 42% 44% Europe / Middle East / Africa
Slide 8: Five pillars update: Investing to drive solid post-pandemic business expansion
Five pillars update: Investing to drive solid post-pandemic business expansion 2021 CER Updated 2021 CER expectations expectations Post-COVID dynamics Q2 2021 update (December 2020) (July 2021) Sample • Sustainable low- to • Workflow Configurator launched to simplify >$750 m >$750 m technologies mid
Slide 9: 2021 sales outlook: Updated perspectives
2021 sales outlook: Updated perspectives (As of July 12, 2021) (In $ millions at CER) At least 12% CER ~$2.2 bn ~$2.1 bn ~ -$110 m ~ -$200 m ~ +$90 m ~ -$70 m Antigen testing ~ +$30 m Sample tech (DNA) ~ -$60 m QIAstat-Dx ~ +$25 m QuantiFERON ~ -$40 m NeuMoDx ~ +$35 m Rest of portfolio ~ -$30 m Samp
Slide 10: Q3 and FY 2021: Outlook and assumptions
Q3 and FY 2021: Outlook and assumptions Updated (As of July 12, 2021) Q3 2021 outlook FY 2021 outlook ~0% CER ≥ +12% CER Net sales (Prior year: $483.8 m) (Prior year: $1,870.3 m) Anticipated currency impact(1) ~ +1-2 p.p. ~ +2-3 p.p. ~$0.52-0.53 CER ≥ $2.42 CER Adjusted EPS(2) (Prior year: $0.58) (P
Slide 11: Summary
Summary 1 Exceeded Q2 2021 outlook: 24% CER sales growth and expected $0.65-0.66 CER adj. EPS 1 2 Very strong non-COVID product group sales: +52% CER in Q2 2021, represented 72% of sales 2 3 Faster-than-expected vaccination success leading to reduced COVID-19 testing demand 4 Updated FY 2021 outlook
Slide 12: Your contacts
Your contacts John Gilardi Vice President Corporate Communications and IR Calendar Phone: +49 2103 29 11711 Q2 2021 full results July 29, 2021 +1 240 686 2222 Mobile: +49 152 018 11711 Q3 2021 results November 2021 E-mail: john.gilardi@qiagen.com Q4 2021 results February 2022 Phoebe Loh Senior Direc